Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Fox Run Management L.L.C.

Fox Run Management L.L.C. grew its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 93.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 62,570 shares of the biopharmaceutical company's stock after acquiring an additional 30,162 shares during the period. Fox Run Management L.L.C.'s holdings in Amicus Therapeutics were worth $589,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. KLP Kapitalforvaltning AS purchased a new stake in Amicus Therapeutics in the 4th quarter valued at approximately $462,000. AXQ Capital LP acquired a new position in Amicus Therapeutics during the fourth quarter worth $171,000. Sciencast Management LP acquired a new stake in Amicus Therapeutics in the fourth quarter valued at $100,000. Semanteon Capital Management LP boosted its position in shares of Amicus Therapeutics by 40.9% during the 4th quarter. Semanteon Capital Management LP now owns 149,156 shares of the biopharmaceutical company's stock worth $1,405,000 after purchasing an additional 43,288 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its stake in shares of Amicus Therapeutics by 18.3% during the 4th quarter. Teacher Retirement System of Texas now owns 65,927 shares of the biopharmaceutical company's stock worth $621,000 after purchasing an additional 10,218 shares during the period.

Amicus Therapeutics Trading Down 1.9 %

FOLD traded down $0.16 during midday trading on Friday, hitting $8.43. The company's stock had a trading volume of 3,686,661 shares, compared to its average volume of 2,517,744. Amicus Therapeutics, Inc. has a 52-week low of $8.37 and a 52-week high of $12.65. The firm has a 50-day moving average price of $9.28 and a two-hundred day moving average price of $9.97. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The firm has a market cap of $2.59 billion, a P/E ratio of -46.83, a PEG ratio of 1.51 and a beta of 0.69.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Morgan Stanley restated an "equal weight" rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Wells Fargo & Company lowered their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.